Cargando…

EBUS-TBNA in PET-positive lymphadenopathies in treated cancer patients

Mediastinal lymph node enlargement is common in the follow-up of patients with previously treated malignancies. The aim of this study is to assess the role of endobronchial ultrasound (EBUS) transbronchial needle aspiration (TBNA) for cyto-histological evaluation of positron emission tomography with...

Descripción completa

Detalles Bibliográficos
Autores principales: Guarize, Juliana, Casiraghi, Monica, Donghi, Stefano, Casadio, Chiara, Diotti, Cristina, Filippi, Niccolò, Di Tonno, Clementina, Midolo, Valeria, Maisonneuve, Patrick, Brambilla, Daniela, Grana, Chiara Maria, Petrella, Francesco, Spaggiari, Lorenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651815/
https://www.ncbi.nlm.nih.gov/pubmed/29071277
http://dx.doi.org/10.1183/23120541.00009-2017
_version_ 1783272954457489408
author Guarize, Juliana
Casiraghi, Monica
Donghi, Stefano
Casadio, Chiara
Diotti, Cristina
Filippi, Niccolò
Di Tonno, Clementina
Midolo, Valeria
Maisonneuve, Patrick
Brambilla, Daniela
Grana, Chiara Maria
Petrella, Francesco
Spaggiari, Lorenzo
author_facet Guarize, Juliana
Casiraghi, Monica
Donghi, Stefano
Casadio, Chiara
Diotti, Cristina
Filippi, Niccolò
Di Tonno, Clementina
Midolo, Valeria
Maisonneuve, Patrick
Brambilla, Daniela
Grana, Chiara Maria
Petrella, Francesco
Spaggiari, Lorenzo
author_sort Guarize, Juliana
collection PubMed
description Mediastinal lymph node enlargement is common in the follow-up of patients with previously treated malignancies. The aim of this study is to assess the role of endobronchial ultrasound (EBUS) transbronchial needle aspiration (TBNA) for cyto-histological evaluation of positron emission tomography with (18)fluorodeoxyglucose (PET) positive mediastinal and hilar lymph nodes developed in patients with previous malignancies. All EBUS-TBNA cases performed from January 2012 to May 2016 were retrospective reviewed. Results of EBUS-TBNA in patients with mediastinal and/or hilar lymphadenopathies were analysed. Non-malignant cytopathologies were confirmed with surgical procedures or clinical and radiological follow-up. Among 1780 patients, 176 were included in the analysis. 103 of these (58.5%) had a diagnosis of tumour recurrence whereas 73 (41.5%) had a different diagnosis: 63 (35.8%) had a non-neoplastic diagnosis and 8 patients (4.6%) had a different cell type malignancy. Samples were false-negative in 5 (2.8%) out of 176 patients. The overall sensitivity, specificity, negative predicted value and diagnostic accuracy were 95.7% (95% CI 90.2–98.6%), 100% (95% CI 94.0–100%), 92.3% (95% CI 83.2–96.7%) and 97.2% (95% CI 93.5–98.8%), respectively. EBUS-TBNA demonstrated a pathological diagnosis different from the previous tumour in a large percentage of patients, confirming its strategic role in the management of patients with previously treated malignancies.
format Online
Article
Text
id pubmed-5651815
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher European Respiratory Society
record_format MEDLINE/PubMed
spelling pubmed-56518152017-10-25 EBUS-TBNA in PET-positive lymphadenopathies in treated cancer patients Guarize, Juliana Casiraghi, Monica Donghi, Stefano Casadio, Chiara Diotti, Cristina Filippi, Niccolò Di Tonno, Clementina Midolo, Valeria Maisonneuve, Patrick Brambilla, Daniela Grana, Chiara Maria Petrella, Francesco Spaggiari, Lorenzo ERJ Open Res Original Articles Mediastinal lymph node enlargement is common in the follow-up of patients with previously treated malignancies. The aim of this study is to assess the role of endobronchial ultrasound (EBUS) transbronchial needle aspiration (TBNA) for cyto-histological evaluation of positron emission tomography with (18)fluorodeoxyglucose (PET) positive mediastinal and hilar lymph nodes developed in patients with previous malignancies. All EBUS-TBNA cases performed from January 2012 to May 2016 were retrospective reviewed. Results of EBUS-TBNA in patients with mediastinal and/or hilar lymphadenopathies were analysed. Non-malignant cytopathologies were confirmed with surgical procedures or clinical and radiological follow-up. Among 1780 patients, 176 were included in the analysis. 103 of these (58.5%) had a diagnosis of tumour recurrence whereas 73 (41.5%) had a different diagnosis: 63 (35.8%) had a non-neoplastic diagnosis and 8 patients (4.6%) had a different cell type malignancy. Samples were false-negative in 5 (2.8%) out of 176 patients. The overall sensitivity, specificity, negative predicted value and diagnostic accuracy were 95.7% (95% CI 90.2–98.6%), 100% (95% CI 94.0–100%), 92.3% (95% CI 83.2–96.7%) and 97.2% (95% CI 93.5–98.8%), respectively. EBUS-TBNA demonstrated a pathological diagnosis different from the previous tumour in a large percentage of patients, confirming its strategic role in the management of patients with previously treated malignancies. European Respiratory Society 2017-10-23 /pmc/articles/PMC5651815/ /pubmed/29071277 http://dx.doi.org/10.1183/23120541.00009-2017 Text en Copyright ©ERS 2017 http://creativecommons.org/licenses/by-nc/4.0/ This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
spellingShingle Original Articles
Guarize, Juliana
Casiraghi, Monica
Donghi, Stefano
Casadio, Chiara
Diotti, Cristina
Filippi, Niccolò
Di Tonno, Clementina
Midolo, Valeria
Maisonneuve, Patrick
Brambilla, Daniela
Grana, Chiara Maria
Petrella, Francesco
Spaggiari, Lorenzo
EBUS-TBNA in PET-positive lymphadenopathies in treated cancer patients
title EBUS-TBNA in PET-positive lymphadenopathies in treated cancer patients
title_full EBUS-TBNA in PET-positive lymphadenopathies in treated cancer patients
title_fullStr EBUS-TBNA in PET-positive lymphadenopathies in treated cancer patients
title_full_unstemmed EBUS-TBNA in PET-positive lymphadenopathies in treated cancer patients
title_short EBUS-TBNA in PET-positive lymphadenopathies in treated cancer patients
title_sort ebus-tbna in pet-positive lymphadenopathies in treated cancer patients
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651815/
https://www.ncbi.nlm.nih.gov/pubmed/29071277
http://dx.doi.org/10.1183/23120541.00009-2017
work_keys_str_mv AT guarizejuliana ebustbnainpetpositivelymphadenopathiesintreatedcancerpatients
AT casiraghimonica ebustbnainpetpositivelymphadenopathiesintreatedcancerpatients
AT donghistefano ebustbnainpetpositivelymphadenopathiesintreatedcancerpatients
AT casadiochiara ebustbnainpetpositivelymphadenopathiesintreatedcancerpatients
AT diotticristina ebustbnainpetpositivelymphadenopathiesintreatedcancerpatients
AT filippiniccolo ebustbnainpetpositivelymphadenopathiesintreatedcancerpatients
AT ditonnoclementina ebustbnainpetpositivelymphadenopathiesintreatedcancerpatients
AT midolovaleria ebustbnainpetpositivelymphadenopathiesintreatedcancerpatients
AT maisonneuvepatrick ebustbnainpetpositivelymphadenopathiesintreatedcancerpatients
AT brambilladaniela ebustbnainpetpositivelymphadenopathiesintreatedcancerpatients
AT granachiaramaria ebustbnainpetpositivelymphadenopathiesintreatedcancerpatients
AT petrellafrancesco ebustbnainpetpositivelymphadenopathiesintreatedcancerpatients
AT spaggiarilorenzo ebustbnainpetpositivelymphadenopathiesintreatedcancerpatients